Q32 Bio QTTB 深 滬
交易中 11-11 11:00:17 美东时间
9.34
+0.010
+0.11%
華盛通- 最 高9.44
- 今 開9.39
- 成交量 3.00万股
- 最 低 9.275
- 昨 收 9.33
- 總市值 2.79亿
- 52周最高 23.5699
- 市盈率 靜 3.86
- 換手率 0.10%
- 52周最低 1.98
- 委 比 -39.73%
- 總股本 2992.39万
- 歷史最高 572.40
- 量 比 0.46
- 振 幅 1.77%
- 歷史最低 1.345
- 每 手 1
- 風險率 4.48%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多凯雷Q3依然偏爱医疗保健板块 Medline(MDLN.US)与StandardAero(SARO.US)持仓占比逾98%
根据美国证券交易委员会(SEC)披露，凯雷(CG.US)递交了截至2026年9月30日的第三季度持仓报告(13F)。 第三季度，凯雷持仓总市值为约83.61亿美...
11-09 16:59
美股大行评级 | 潜在涨幅386.16%！摩根士丹利维持TeraWulf"超配"评级，上调目标价至65美元
今日重点评级关注：摩根士丹利：维持TeraWulf"超配"评级，目标价从62.5美元升至65美元；摩根士丹利：维持Hut 8"超配"评级，目标价从273美元升至275美元
10-13 12:30
Leerink Partners Initiates Coverage On Q32 Bio with Outperform Rating, Announces Price Target of $40
Leerink Partners analyst Will Soghikian initiates coverage on Q32 Bio (NASDAQ:QTTB) with a Outperform rating and announces Price Target of $40.
10-12 20:25
美股大行评级 | 潜在涨幅919.61%！HC Wainwright上调NeuroSense Therapeutics目标价至52美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持NeuroSense Therapeutics"买入"评级，目标价从8美元升至52美元；HC Wainwright & Co.：维持艾切托"买入"评级，目标价从27美元升至34美元
09-29 08:33
Jefferies Initiates Coverage On Q32 Bio with Buy Rating, Announces Price Target of $29
Jefferies analyst Maury Raycroft initiates coverage on Q32 Bio (NASDAQ:QTTB) with a Buy rating and announces Price Target of $29.
09-28 22:01
Gene editing stocks fall after Anthropic’s CRISPR-like discovery
Gene editing companies traded lower on Wednesday after Anthropic (ANTHRO) said that its AI model Claude has “autonomously discovered” a new enzyme system similar to the gene-editing tool CRISPR. Notab...
09-24 02:33
Small-cap stocks with strong momentum grades and triple-digit YTD gains
A group of U.S. small-cap stocks is flashing A+ momentum grades in the latest quantitative screen, with several names posting triple-digit gains year to date. Seeking Alpha's Quant Momentum Grade meas...
09-17 21:55
Q32 Bio Appoints José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer
-- Dr. Trevejo is a physician-scientist and biotechnology executive with over 20 years of experience spanning dermatology and late-stage clinical development -- -- Dr. Hershberger is a drug ...
09-14 18:59
Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases
Akebia Therapeutics启动II期临床试验，评估ebribafusp治疗IgA肾病、狼疮性肾炎和C3肾小球病的效果。ebribafusp是一种 investigational 的下一代抗C3d因子H融合蛋白，旨在抑制组织中的补体激活，而不影响血液中的补体系统。试验计划招募最多30名患者，每周一次皮下注射，持续26周，随后是长期扩展研究。主要终点是不良事件的发生率，次要终点包括蛋白尿变化、肾功能和药代动力学。Akebia Therapeutics专注于改善肾脏疾病患者的生活，并在2025年从Q32 Bio获得了ebribafusp的全球权利。初步数据预计在2027年公布。
09-14 12:00
Quant Check: Top- and bottom-rated small-cap healthcare stocks post-earnings
As earnings season ends, investors are turning to updated Quant ratings to see how companies stack up after their latest results. These ratings grade stocks on key metrics like value, growth, profits,...
09-01 22:25
